<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974141</url>
  </required_header>
  <id_info>
    <org_study_id>225678-006</org_study_id>
    <nct_id>NCT01974141</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of dapsone gel versus vehicle control in
      patients with acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Patients with None or Minimal on the 5-Point Global Acne Assessment Score (GAAS) Scale</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Inflammatory Facial Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Noninflammatory Facial Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in Lesion Counts</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting &quot;Very Good&quot; or &quot;Excellent&quot; in the Assessment of Facial Appearance on a 5-Point Scale</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the 9-Item Acne Symptom and Impact Scale (ASIS) Sign Domain Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting at Least a 1-Grade Improvement from Baseline in Oiliness on a 5-Point Scale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting at Least a 1-Grade Improvement from Baseline in Redness on a 5-Point Scale</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2156</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Dapsone Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapsone Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone Gel</intervention_name>
    <description>Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
    <arm_group_label>Dapsone Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone Gel Vehicle</intervention_name>
    <description>Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.</description>
    <arm_group_label>Dapsone Gel Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acne vulgaris

          -  Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight,
             tanning beds) throughout the study

        Exclusion Criteria:

          -  Severe cystic acne, acne conglobata, acne fulminans, or secondary acne

          -  Use of phototherapy devices (eg, ClearLight™), energy-based devices, adhesive
             cleansing strips (eg, Pond's®, Biore®), or cosmetic procedures (eg, facials, peeling,
             comedo extraction) in the past week

          -  Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics,
             antibacterials (including benzoyl peroxide-containing products [eg, benzamycin]),
             retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps
             such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium
             sulfacetamide) in the past 2 weeks

          -  Use of birth control pills strictly for acne control
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.acneclinicalstudy.com</url>
    <description>Study Website</description>
  </link>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 17, 2014</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
